Randomised comparison study: eradication therapy for Helicobacter pylori with or without ecabet sodium after endoscopic submucosal dissection (ESD) of early gastric cancer - Quadruple eradication therapy with ecabet sodium of early gastric cancer after ESD.

Department of Gastroenterology, Kitasato University School of Medicine0 个研究点目标入组 330 人开始时间: 2012年4月12日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1 Patients with past H.pylori eradication therapy. 2. Patients with suspected gastrointestinal stenosis and diagnosed gastrointestinal stenosis. 3. Patients with a history of upper gastrointestinal tract ablative operation or the vagotomy. 4. Patients with the active overlap cancer except the gastric cancer. 5. Patients with severe liver, renal, cardiac or hematopoietic dysfunction. 6. Patients with hypersensitivity to ecabet sodium. 7. Pregnant or lactating women or women who intended to become pregnant during the study period. 8. Patients with a history of allergy to omeprazole, amoxicilline, clarithromycin, or penicilline. 9. Patients receiving atazanavir sulfate, pimozide, ergotamine component preparation, tadalafil(adcirca). 10. Patients with mononucleosis. 11. Inadequate to entry judged by investigator.

发起方

Department of Gastroenterology, Kitasato University School of Medicine